News Summary
Kamada Ltd. has gained FDA approval for a new plasma collection center in Houston, Texas. This facility, encompassing 12,000 square feet with 50 donor beds, is expected to generate $8-10 million in annual revenue. The center will focus on both regular and specialty plasma collection, supporting Kamada’s growth in the specialty plasma market. With a strong financial position, the company also plans future expansions and approvals, aiming to meet the increasing demand in the sector.
Houston, Texas
Kamada Ltd. has received approval from the U.S. Food and Drug Administration (FDA) for its new plasma collection center located in Houston, Texas. This facility, which is a key expansion for the company, is projected to generate between $8 million to $10 million in annual revenue when operating at full capacity.
The FDA’s approval follows a thorough on-site inspection that took place during the second quarter of this year. This approval serves as a supplement to Kamada’s existing Biologics License Application (BLA), solidifying the company’s compliance with regulatory standards required to operate a facility of this nature.
Facility Details and Revenue Potential
Located in a 12,000 square foot space, the Houston center is equipped with 50 donor beds, making it one of the largest sites for specialty plasma collection in the United States. The facility aims to achieve an annual collection capacity of approximately 50,000 liters of plasma. In addition to regular source plasma, the center will also focus on collecting specialty plasma, including products such as Anti-Rabies and Anti-D.
This new facility is part of Kamada’s broader strategy to enhance its position in the specialty plasma market. The anticipated revenue from the Houston center represents a 5-6% increase relative to Kamada’s current revenue base of $167 million.
Company Overview and Financial Performance
Kamada is a biopharmaceutical firm with a market capitalization of $416 million. The company has recorded robust financial health metrics, including a strong current ratio of 3.3, indicating it has more cash than debt. Over the last twelve months, Kamada has achieved a revenue growth rate of 11.8%.
In its first-quarter financial results for the year 2025, Kamada reported a 17% increase in revenue, reaching $44 million, which was in line with analysts’ expectations. The company’s earnings per share increased from $0.04 to $0.07 during the same quarter last year. A substantial portion of this revenue growth can be attributed to a 19% rise in proprietary product sales and increased sales of Varizig in North America.
Expansion Plans and Future Approvals
After securing FDA approval for the Houston center, Kamada also plans to seek further inspection and approval from the European Medicines Agency. The company already operates two additional plasma collection centers in Texas, specifically in San Antonio and Beaumont. The center in San Antonio is similarly projected to generate between $8 million to $10 million in annual revenue and opened its doors in March 2025.
Market Position and Analyst Ratings
The recent FDA approval further strengthens Kamada’s competitive position in the specialty plasma market as the company continues its efforts to expand. Current analyst ratings for Kamada stock maintain a Hold status, with a price target set at $15.00.
In summary, the approval of the Houston plasma collection center marks a significant milestone for Kamada Ltd., contributing to its ongoing growth and commitment to providing plasma-derived therapies for rare and serious conditions. With its expansion into Houston, the company not only aims to enhance its production capabilities but is also focused on meeting increasing demand in the specialty plasma sector.
Deeper Dive: News & Info About This Topic
HERE Resources
Additional Resources
- Investing.com: FDA Approves Kamada’s Houston Plasma Collection Center
- Wikipedia: U.S. Food and Drug Administration
- TipRanks: Kamada’s Houston Plasma Center Gains FDA Approval
- Google Search: Kamada Houston Plasma Collection Center FDA Approval
- GlobeNewswire: Kamada Announces Expansion of Plasma Collection Operations in Texas
- Encyclopedia Britannica: Plasma
Author: STAFF HERE HOUSTON TX WRITER
HOUSTON STAFF WRITER The HOUSTON STAFF WRITER represents the experienced team at HEREHouston.com, your go-to source for actionable local news and information in Houston, Harris County, and beyond. Specializing in "news you can use," we cover essential topics like product reviews for personal and business needs, local business directories, politics, real estate trends, neighborhood insights, and state news affecting the area—with deep expertise drawn from years of dedicated reporting and strong community input, including local press releases and business updates. We deliver top reporting on high-value events such as Houston Livestock Show and Rodeo, Art Car Parade, and Chevron Houston Marathon. Our coverage extends to key organizations like the Greater Houston Partnership and Houston Area Urban League, plus leading businesses in energy and healthcare that power the local economy such as ExxonMobil, Schlumberger, and Houston Methodist. As part of the broader HERE network, including HEREAustinTX.com, HERECollegeStation.com, HEREDallas.com, and HERESanAntonio.com, we provide comprehensive, credible insights into Texas's dynamic landscape.
